Dilsher S. Dhoot, MD
Show Description +
Dr. Dhoot highlights 3-year efficacy and safety data for pegcetacoplan (Syfovre, Apellis) for subfoveal GA; every-other-month treatment led to a 24% reduction in lesion growth at 36 months.
Posted: 10/29/2024
Dilsher S. Dhoot, MD
Dr. Dhoot highlights 3-year efficacy and safety data for pegcetacoplan (Syfovre, Apellis) for subfoveal GA; every-other-month treatment led to a 24% reduction in lesion growth at 36 months.
Posted: 10/29/2024
Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of AAO: 2024.
Please log in to leave a comment.